Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial - Brown, David; Gründer, Gerhard (Schizophrenia bulletin, 2019)
Gesehen am 16.05.2019